Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israeli strikes in Gaza kill 25 people, Hamas health authority says - 2Germany sees third consecutive diesel price record after rule change
- 3Oil magnate’s Venezuela detainment spooks industry
- 4The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- 5Birutė Galdikas: The last of the ‘angels’ in primatology’s most extraordinary chapter
- Ocean side Locations for a Family Excursion
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Iranian strikes on Israel injure 11 and set chemical plant ablaze
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- New funding transforms lives by expanding electricity access across Africa
- Malaysia To Revive Search for Missing Flight MH370
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- Crew-11 astronauts undock in 1st-ever medical evacuation from the International Space Station (video)
- Artemis 2 astronaut Victor Glover delivers inspiring Easter message on the way to the moon (video)
